The invention relates to medical applications of the HDAC inhibitor resminostat ((E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl) -1H-pyrrol-3-yl]-N-hydroxy-acrylamide) or a salt or solvate thereof in the treatment of benign or malignant neoplasia in a human subject, wherein said human subject is an Asian, and wherein said treatment comprises administering resminostat or a salt or solvate thereof to said human subject in a daily dose of less than 600 mg resminostat, and administering at least one further chemotherapeutic agent to said human subject.本發明涉及HDAC抑制劑瑞米司他(resminostat) (E)-3-[1-(4-二甲基胺基甲基-苯磺醯基)-1H-吡咯-3-基]-N-羥基-丙烯醯胺)或其鹽或溶劑合物在人類受試者中治療良性或惡性瘤變之醫療應用,其中所述的人類受試者係亞洲人,並且其中所述治療包括將瑞米司他或其鹽或溶劑合物以少於600 mg瑞米司他的每日劑量給予所述人類受試者,並且給予所述人類受試者至少一種另外的化學治療劑。
